STS News, Winter 2020 — The third annual STS/EACTS Latin America Cardiovascular Surgery Conference attracted its largest audience yet—more than 300 cardiac surgeons, scholarship recipients, and industry representatives from 33 countries—to Cancun, Mexico, in late November.
The international faculty explored new developments and best practices in treating cardiac and congenital heart diseases and encouraged audience members to challenge the science and use the best treatment options possible for their patients.
"I do believe that there will be innovation in transcatheter mitral valve repair. There will be a transcatheter recreation of the surgical tools we have for mitral repair, and mitral repair will remain the gold standard."
Joseph F. Sabik III, MD, provided context for the ISCHEMIA trial, which concluded that watchful waiting combined with medical management was better than percutaneous coronary intervention or coronary artery bypass grafting for patients with stable angina.
“Despite the hundreds of millions of dollars that were spent on this study, it means very little for cardiac surgeons. The devil is in the details, and this trial included very few patients who were even eligible for surgery,” Dr. Sabik explained.
Panelists and audience members also discussed the MOMENTUM 3, PARTNER 3, RECOVERY, EVEREST II, and Evolut Low-Risk TAVR trials.